DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C
DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C
[Kuala Lumpur, Geneva20 September 2017] Malaysia has issued a “government use” licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with hepatitis C in Malaysia access sofosbuvir, and could have important repercussions in the global effort to secure access to expensive treatments for this viral disease. [Bahasa] [Español] [Português]
DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C
Pooling patient data could improve visceral leishmaniasis treatment options
Pooling patient data could improve visceral leishmaniasis treatment options
Combining patient data from visceral leishmaniasis clinical trials would give scientists and clinicians more tools to understand and treat the disease which can be fatal if untreated.
Pooling patient data could improve visceral leishmaniasis treatment options
More than EUR 56 million raised to fund initiative to fight antibiotic resistance
More than EUR 56 million raised to fund initiative to fight antibiotic resistance
[Berlin - 4 September 2017] Germany hosts pledging event for GARDP, a new initiative to develop new antibiotic treatments Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research. [Deutsch]
More than EUR 56 million raised to fund initiative to fight antibiotic resistance
U.S. FDA approves Chemo Group's benznidazole to treat children with Chagas disease
U.S. FDA approves Chemo Group's benznidazole to treat children with Chagas disease
[Washington DC, Geneva - 31 August 2017] On August 29th, the U.S. Food and Drug Administration (FDA) approved Chemo Research’s New Drug Application (NDA) for benznidazole. This is the first drug ever approved by the FDA to treat Chagas disease. [Español] [Português]
U.S. FDA approves Chemo Group's benznidazole to treat children with Chagas disease
See all news

Scientific Articles

See all scientific articles

Events

  • 8th Trends in Medical Mycology October 6-9, 2017 Belgrade, Serbia Jean-Robert Ioset, Discovery Manager, and Benjamin Perry, Senior Discovery Manager – Open Innovation, presented posters at the meeting.
  • ECTMIH 2017 October 16-20, 2017 Antwerp, Belgium DNDi presented on sleeping sickness, visceral leishmaniasis, mycetoma, and onchocerciasis.
  • ASTMH 2017 November 5-9, 2017 Baltimore, Maryland, USA DNDi will be taking part in symposia, posters and oral presentations at the meeting.
  • Joint Meeting of Bioscience Societies November 13-17, 2017 Buenos Aires, Argentina DNDi Latin America will give an update on the latest advances in therapeutic biomarkers or prognosis of Chagas disease.
  • II International Symposium on Biological Sciences November 22, 2017 Minas Gerais, Brasil Sergio Sosa-Estani, Head of Chagas, DNDi Latin America will present on Chagas disease at the event.
See all events